A familiar Paris Metro sign

To get around Paris efficiently, we might start off at one particular Metro station and need to change lines or direction several times in order to arrive at our destination on the other side of the city.

Similarly, I’ve often wondered if repeating endocrine or hormonal therapies in breast or prostate cancers is a big like staying on the same line and never getting to where we really need to go.

Just as CDK4/6 inhibitors revolutionised the treatment of HR+/HER2- advanced breast cancer by allowing physicians to target a different pathway or axis, should we be rethinking new approaches to an old problem?

In our latest story from the ESMO22 conference, we explore some of the emerging evidence…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by